Literature DB >> 24393748

Aspirin for cardioprotection and strategies to improve patient adherence.

Danielle Duffy1, Erik Kelly, Amanda Trang, David Whellan, Geoffrey Mills.   

Abstract

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in North America. Aspirin therapy has proven clinical effectiveness in the prevention and treatment of CVD and is one of the most widely used drugs nationwide. However, despite the medication's popularity and utility, adherence to a proper aspirin regimen is suboptimal, resulting in adverse health outcomes and increased health care costs. Our review outlines current knowledge on aspirin therapy adherence, causes of nonadherence, and strategies available to increase adherence to aspirin and medications in general. We demonstrate that, indeed, aspirin adherence rates are suboptimal, ranging from 72% to 92%, and that a combination of patient- and medication-related factors contribute to nonadherence. A multidimensional approach involving patient education and medication innovations to reduce aspirin side effects is imperative to improving rates of aspirin therapy adherence.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24393748     DOI: 10.3810/pgm.2014.01.2721

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  5 in total

1.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly.

Authors:  John J McNeil; Rory Wolfe; Robyn L Woods; Andrew M Tonkin; Geoffrey A Donnan; Mark R Nelson; Christopher M Reid; Jessica E Lockery; Brenda Kirpach; Elsdon Storey; Raj C Shah; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Michael Jelinek; Mobin Malik; Charles B Eaton; Donna Brauer; Geoff Cloud; Erica M Wood; Suzanne E Mahady; Suzanne Satterfield; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

Review 2.  PA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.

Authors:  Danielle Duffy; Bridget Rooney; Suzanne Adams; David J Whellan
Journal:  Expert Rev Cardiovasc Ther       Date:  2014-10-10

3.  Perioperative aspirin and long-term survival in patients undergoing coronary artery bypass graft.

Authors:  Qian Ding; Hong Liu; Zugui Zhang; Jordan Goldhammer; Eric Yuen; Zhongmin Li; Linong Yao; Nilas Young; Douglas Boyd; William Weintraub; Rohinton Morris; Jianzhong Sun
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379

4.  Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.

Authors:  Shuai Yuan; Peng Chen; Huaping Li; Chen Chen; Feng Wang; Dao Wen Wang
Journal:  J Cell Mol Med       Date:  2020-12-18       Impact factor: 5.295

5.  Patient Preferences of Low-Dose Aspirin for Cardiovascular Disease and Colorectal Cancer Prevention in Italy: A Latent Class Analysis.

Authors:  Tommi Tervonen; Pareen Vora; Jaein Seo; Nicolas Krucien; Kevin Marsh; Raffaele De Caterina; Ulrike Wissinger; Montse Soriano Gabarró
Journal:  Patient       Date:  2021-04-08       Impact factor: 3.883

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.